Randomization and masking
Eligible patients were randomly assigned using an Interactive Web Response System in a 2:1 ratio to receive 0.3 mg PEG-Loxe (Hansoh Pharma) or 1500 mg metformin (Merck). Randomization was stratified according to the following two variables:BMI: 25.0–29.9 kg/mPre-trial treatment: lifestyle interventions or OAD therapy.Moreover, the clinical trial statistician was blinded to the two groups during data analysis.